Last edition
News about "Carine Boustany"
Boehringer Ingelheim Licenses Inflammation Antibody Program from Immunitas Therapeutics
Boehringer Ingelheim licenses a first-in-class antibody program from Immunitas Therapeutics to develop targeted therapies for chronic inflammatory diseases and expand its immunology pipeline.
Carine Boustany | 14/05/2026 | By News Bureau
Boehringer and Simcere Partner on Dual-Target IBD Antibody
Boehringer Ingelheim has signed a licence and collaboration deal with Simcere to develop a novel TL1A/IL23p19 bispecific antibody for inflammatory bowel disease, gaining global rights outside greater China, with Simcere eligible for up to €1.058 billion in payments.
Carine Boustany | 29/01/2026 | By News Bureau | 115
Boehringer Ingelheim Acquires Licence from Kyowa Kirin to Develop Treatment for Autoimmune Diseases
Boehringer Ingelheim has acquired a licence from Kyowa Kirin to develop a small molecule programme targeting autoimmune diseases. The collaboration aims to address significant unmet medical needs and strengthen Boehringer’s pipeline of innovative therapies for patients with inflammatory and immune-related conditions.
Carine Boustany | 31/10/2025 | By Dineshwori | 248
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy